Ingredient queries for MEDVi QUAD often stop at “what is PT-141,” because affiliate pages misuse the name.
What Is Pt-141?
PT-141 (bremelanotide) acts on melanocortin pathways linked to sexual desire in its approved female HSDD product (Vyleesi). It is not a PDE5 inhibitor. It is not Levitra. Levitra’s active is vardenafil, a different molecule that appeared in an older public QUAD-style formula story alongside apomorphine on some stale pages.
In the July 2026 brand-facing MEDVi QUAD list, PT-141 sits with sildenafil, tadalafil, and L-citrulline in a compounded sublingual liquid. Class facts about Vyleesi do not equal combo-trial proof for that liquid in men with ED.
Side-Effect Context
Labeled bremelanotide products discuss nausea, flushing, and blood-pressure changes among other risks. Stacked with two PDE5 drugs, the side-effect surface can widen. Read side effects and what's in the formula.
Up: review · dosing caution
Sources Checked for This Page
- FDA labels for sildenafil, tadalafil, and bremelanotide (Vyleesi) for ingredient-class facts, not as approval of the QUAD combo.
- FDA warning letter MEDVi 721455 (20 February 2026) where brand trust context is relevant.
- 2026 brand-facing price, cancel, shipping, and formula statements treated as seller claims.
Individual ingredients such as sildenafil and tadalafil are FDA-approved for other indications; the combined compounded formulation has not been evaluated by the FDA as a finished product, standard for all compounded medicines.
This content is informational, not medical advice.